Annals of hepatology最新文献

{"title":"Prevalence and evaluation of sleep disturbances in Mexican patients with hepatic cirrhosis through the application of the Pittsburgh sleep questionnaire","authors":"María I. Badillo-Vázquez ,&nbsp;Raúl Contreras-Omaña","doi":"10.1016/j.aohep.2025.101836","DOIUrl":"10.1016/j.aohep.2025.101836","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>According to the literature, patients with cirrhosis have a high prevalence of sleep disturbances, which increase as the disease progresses. There are few studies conducted in this patient group, with a small number of samples, reflecting alterations in sleep quality and rest. The Pittsburgh Sleep Quality Index (PSQI) is a tool that allows us to evaluate sleep quality and the level of disturbances it may present. To assess the type and prevalence of sleep disturbances in a Mexican group of patients with cirrhosis through the application of the Pittsburgh questionnaire.</div></div><div><h3>Materials and Patients</h3><div>A prospective, cross-sectional, and epidemiological study was conducted with 300 individuals, of whom 266 did not have hepatic diseases and 74 were diagnosed with cirrhosis.</div><div>The Pittsburgh questionnaire was administered to them, which consists of 7 components that generate a total score. Total scores were interpreted as follows: 1-4 without sleep disturbances, 5-7 with mild disturbance, 8-14 with moderate disturbance, and 15 or more indicating severe disturbance.</div><div>Results were compared using Odds Ratio (OR) to assess the effect.</div></div><div><h3>Results</h3><div>Of the individuals evaluated, 74 (24.66%) were diagnosed with cirrhosis, with 42 women (56%) and 32 men (43.24%). The remaining 226 participants (75.33%) did not have liver diseases, with 150 women (66.3%) and 75 men (33.1%). When comparing the total scores, it was observed that 57 people without sleep disturbances, 18 (31.57%) were in the cirrhosis group, while 39 (68.42%) were not. Additionally, of the 102 individuals with mild alterations, 20 (19.60%) were in the cirrhosis group and 82 (80.39%) were not. Of the 131 individuals with moderate alterations, 32 (24.42%) had cirrhosis and 99 (75.57%) did not. Finally, of the 10 individuals with severe alterations, 4 (40%) had cirrhosis and 6 (60%) did not. The calculation of the Odds Ratio was 1.09, indicating that patients with cirrhosis had a similar risk of sleep disturbances as those without cirrhosis.</div></div><div><h3>Conclusions</h3><div>In our study, it seems to demonstrate that contrary to previous reports in the literature, no difference was found in the prevalence of sleep disturbances between our population without cirrhosis and patients with cirrhosis.</div><div>This study is the first to apply this validated and translated questionnaire in Spanish to a Mexican population of patients with cirrhosis and healthy individuals to evaluate their sleep quality and the first to have a significant sample.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 ","pages":"Article 101836"},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143896037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Most Common Complications in Patients Post Liver Transplantation at a Hospital in Mexico.","authors":"Saúl A. Vera-Nungaray ,&nbsp;Diego F. Abendaño-Rivera ,&nbsp;Karina Cazarin-Chavez ,&nbsp;María F. Higuera-De la Tijera ,&nbsp;Viridiana López-Ladrón de Guevara ,&nbsp;Isidoro A. Sanchez-Cedillo ,&nbsp;Erika F. Rodriguez-Aguilar ,&nbsp;Victor M. Paez-Zayas","doi":"10.1016/j.aohep.2025.101846","DOIUrl":"10.1016/j.aohep.2025.101846","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Liver transplantation worldwide presents a series of complications that need to be identified to adequately treat and prevent them; however, information about these in Mexico is limited. The objective is to report the epidemiology of these complications in a third-level hospital transplant center in Mexico</div></div><div><h3>Materials and Patients</h3><div>A cohort study was conducted, including post-liver transplant patients from 2019 to 2023. The presence of infectious and postsurgical complications after the event was determined, as well as the rate of both acute and chronic rejection. Data are expressed using descriptive statistics with proportions and percentages for qualitative variables and mean and standard deviation or median and range for quantitative variables.</div></div><div><h3>Results</h3><div>110 patients were included, 46 women and 64 men with a mean age of [insert average age]. Complications were classified according to type and timing of presentation after surgery. Regarding rejection rates, a 10.00% acute rejection was observed with a mean presentation of 7.6±6.6 months, and 2.8% chronic rejection (mean time: 17.7±8.1 months). Results are summarized in Table 1 and Figure 1.</div></div><div><h3>Conclusions</h3><div>Complications in liver transplant recipients are common and jeopardize both patient life and graft function. Although rejection rates remain high, our center presents a favorable epidemiology compared to reported literature, below global rates for acute rejection (15-25%) and chronic rejection (3-17%).</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 ","pages":"Article 101846"},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143896077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The GDF11 represses the Stat3 signaling pathway, conferring metabolic, inflammatory, and oncogenic restrictions in cells derived from human hepatocellular carcinoma.","authors":"Melissa Sánchez-Rodríguez ,&nbsp;Monserrat Gerardo-Ramírez ,&nbsp;Arturo Simoni-Nieves ,&nbsp;María Concepción Gutiérrez-Ruiz ,&nbsp;Roxana U Miranda-Labra ,&nbsp;Verónica Souza ,&nbsp;Leticia Bucio-Ortiz ,&nbsp;Alejandro Escobedo-Calvario ,&nbsp;Luis E. Gomez-Quiroz","doi":"10.1016/j.aohep.2025.101793","DOIUrl":"10.1016/j.aohep.2025.101793","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>GDF11 has shown potential in displaying anti-tumor effects in cells derived from human HCC, but the molecular mechanisms that lead to this, as well as the early transcriptomic response of GDF11 in HCC, remain a mystery. To identify potential targets for therapeutic intervention revealed by GDF11 treatment in HCC.</div></div><div><h3>Materials and Patients</h3><div>Huh7 cells were treated for 12 h with 50 ng/ml of GDF11, and sequencing was performed using the Illumina HiSeq4000 platform. The results were filtered with a p≤0.01, ± 1.5-fold change, and an FDR= 0.05. Functional and enrichment analysis was done using the Ingenuity Pathway Analysis (IPA) program.</div></div><div><h3>Results</h3><div>Our data show 1450 differentially expressed genes. It is observed that GDF11 has a profound impact on highly oncogenic pathways, highlighting the Stat3 pathway, beta-catenin, and HIF-1 alpha, among others. Functional analysis revealed that GDF11 could reduce cholesterol and lipid metabolism in general, inflammation, drug resistance, and stemness capacity. It is noteworthy that tumors grown under a lipid-rich environment exhibit significant activation of Stat3, so the decrease in the molecular signature of Stat3 induced by GDF11 strongly suggests a mechanism mediated by the repression of the pathway of this factor transcription, impacting metabolism, inflammation, differentiation, and drug resistance.</div></div><div><h3>Conclusions</h3><div>Our study's novel finding is that GDF11 represses the Stat3 signaling pathway, thereby imposing metabolic, inflammatory, and oncogenic restrictions. GDF11 represents a good promise in the treatment of HCC.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 ","pages":"Article 101793"},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143896049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Main Characteristics of Portal Venous System Thrombosis in Patients with Advanced Decompensated Chronic Liver Disease","authors":"Diego F. Abendaño-Rivera,&nbsp;Paloma M. Diego-Salazar,&nbsp;Saul A. Vera-Nungaray,&nbsp;Karina Cazarin-Chavez,&nbsp;Mónica Baca-García,&nbsp;Yelba G. Céspedes Saballos,&nbsp;Fátima Higuera-De La Tijera","doi":"10.1016/j.aohep.2025.101794","DOIUrl":"10.1016/j.aohep.2025.101794","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Chronic liver disease (CLD) is common globally; in advanced stages, decompensation and complications such as portal venous system thrombosis (PVST) increase.</div></div><div><h3>Objective</h3><div>To describe the prevalence and main characteristics of hospitalized patients with decompensated CLD and PVST in a tertiary care center.</div></div><div><h3>Materials and Patients</h3><div>An observational, longitudinal, and descriptive study was conducted on hospitalized patients in a tertiary care center in Mexico City with decompensated CLD during the period 2022 and 2023. These patients had imaging studies (CT scan or hepatic Doppler ultrasound) reporting PVST. Follow-up was conducted from the diagnosis of CLD, documentation of PVST, and survival until 2024. Patients with PVST without a diagnosis of CLD or without current follow-up were excluded.</div><div>Data will be analyzed using the SPSS statistical software, version 23. Qualitative variables will be presented as frequencies and percentages, while numerical variables will be shown as means and standard deviations or medians and ranges, as appropriate.</div></div><div><h3>Results</h3><div>We reviewed 788 records of patients with decompensated CLD, of which 60 had PVST, with a period prevalence of 7.6%. Of this group, 20% had hepatocellular carcinoma. Of the total, 37 were women (61.6%), with an average age of 59 ± 9 years. According to the Child-Pugh classification, 6 cases were class A (10%), 25 were class B (42%), and 29 were class C (48%), with an average MELD score of 19.4 and MELD-Na of 21.8. All patients with PVST had at least one prior decompensation before admission (100%), with 43% and 31% having two and three decompensations, respectively. The most frequent etiology was MASLD (48.3%), and the main reason for hospitalization was variceal gastrointestinal bleeding (50%). The portal vein was the most affected vessel (100%), with 20% of cases showing extension to the superior mesenteric vein, of which 76% presented signs of chronicity. The average time from CLD diagnosis to PVST identification was 3.5 ± 2.83 years. By 2024, 41% of patients with PVST had died, with septic shock being the leading cause of death during hospitalization.</div></div><div><h3>Conclusions</h3><div>The prevalence of PVST in our study is similar to that reported in the literature (3-25%). It is more frequent in women, has a metabolic etiology, and primarily affects the portal vein. To date, 41% have died, mainly from septic shock. However, PVST may be an important factor to study in the progression of CLD.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 ","pages":"Article 101794"},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143896050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experience with dexmetomidine in the management of alcohol withdrawal syndrome for patients with cirrhosis","authors":"Liliana I. Gallardo-González,&nbsp;Jose L. Perez-Hernandez,&nbsp;Maria F. Higuera-De la,&nbsp;Tijera,&nbsp;Mary C. Alegría-Ovando","doi":"10.1016/j.aohep.2025.101795","DOIUrl":"10.1016/j.aohep.2025.101795","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Lorazepam is the first-line treatment in patients with alcohol withdrawal syndrome (AWS). In patients with cirrhosis and AWS, the use of dexmetomidine (DXM) has been poorly studied. The objective of this study is to report the effect of DXM in patients with cirrhosis and AWS.</div></div><div><h3>Materials and Patients</h3><div>Observational, retrospective, descriptive and analytical study. Patients with cirrhosis and AWS, treated with lorazepam, DXM, or both, were included. The Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-Ar) data was collected before and after treatment, as well as the days of in-hospital stay (IHS). The quantitative variables were summarized using non-parametric descriptive statistics according to the distribution of the variables (average and range), as well as frequencies and percentages in the case of qualitative variables. To compare between three independent groups, the Kruskal-Wallis (KW) and Jonckheere-Terpstra (JT) tests were used. A significant difference was considered one with a value of p&lt;0.05.</div></div><div><h3>Results</h3><div>39 patients were included, 37 (94.9%) men, average age 41 (27-66) years, alcohol consumption 287 (64-960) g/day, CIWA-Ar at admission 20 (10-46) points, Child -Pugh 10 (5-14) points, MELD-Na 16 (8-40) points. Regarding the AWS treatment: 17 (43.6%) received lorazepam, 13 (33.3%) DXM, and 9 (23.1%) lorazepam + DXM. When compared between groups there were no differences in terms of days of IHS [4 (1-30) vs. 3 (1-18) vs. 2 (1-5) respectively for lorazepam, DXM, lorazepam + DXM; KW p=0.86, JT p=0.82], nor in terms of CIWA-Ar at 24 hours post-treatment [7 (1-19) vs. 6 (0-15) vs. 5 (2-23) respectively for lorazepam, DXM, lorazepam + DXM; KW p=0.19, JT p=0.45]. No serious adverse effects were reported with any of the three strategies.</div></div><div><h3>Conclusions</h3><div>DXM appears to be an effective and safe option for the treatment of AWS in patients with cirrhosis. However, clinical trials are required to validate our findings.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 ","pages":"Article 101795"},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143896051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aggressive intrahepatic cholangiocarcinoma in pregnancy: Case report and literature review","authors":"Alan Galindo-Félix ,&nbsp;Laura Sánchez-Reza ,&nbsp;Emma I. González-Bravo ,&nbsp;Jorge A. Ortega-Tecuátl ,&nbsp;Ana P. Escobedo-Zúñiga","doi":"10.1016/j.aohep.2025.101842","DOIUrl":"10.1016/j.aohep.2025.101842","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction and Objectives&lt;/h3&gt;&lt;div&gt;Cholangiocarcinoma is a very rare type of hepatobiliary cancer and extremely rare reported during pregnancy. Its early and timely diagnosis is complicated. To report a rare and poorly studied case of aggressive intrahepatic cholangiocarcinoma during pregnancy in a 30-year-old patient.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Material and Patients&lt;/h3&gt;&lt;div&gt;Female patient, 30 years old, with antecedent of 2 cesarean sections, one 2 years ago and the second one 1 and a half year ago, without complications and occupational exposure to unspecified pesticides. The clinical picture begins at 32 weeks of gestation characterized by nausea and vomiting of gastric contents, dull pain in the right hypochondrium and weight loss of 7 kg in 2 months, to which generalized jaundice, choluria, acholia, pruritus, nocturnal diaphoresis and ecchymosis; A simple magnetic resonance image was performed and a large liver lesion was identified at the level of liver segments IV and VIII with a maximum diameter of 10.3 cm, suggestive of malignancy associated with the presence of satellite lesions suggestive of infiltration to the rest of the liver parenchyma. It was decided to resolve the pregnancy at 35 weeks of gestation by cesarean section without apparent complications. During the mid-surgical postpartum period simple and contrasted tomography of the abdomen is performed where hepatic, pulmonary, pleural and bone tumor activity and dilation of the intrahepatic bile duct are reported; tumor markers ACE 1.91, CA 19-9 30.89, AFP 149.4; liver biopsy reports metastasis of moderately differentiated adenocarcinoma (g2) consistent with primary bile duct (cholangiocarcinoma); Immunohistochemistry with positivity for ck7, ck19, negative for ck20, gata 3, cdx2, pax8 and hepar1.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;During his in-hospital stay, she presented sinus tachycardia evidenced by ECG, associated with risk factors, and pulmonary thromboembolism was suspected. The ICU service was consulted and they accepted the case, evaluated by cardiology performing an echocardiogram discarding the diagnosis. The general surgery, oncological surgery and oncology services were consulted and commented that she was not a candidate for surgical or systemic treatment for advanced disease clinical stage IV.&lt;/div&gt;&lt;div&gt;She was discharged from the hospital with palliative measures and two weeks later she was re-admitted to the emergency department due to generalized tonic-clonic seizures advanced airway manage was performed and vasopressor support was decided; simple skull tomography without metastatic activity; presented clinical deterioration and progression of the disease leading to multiple organ failure. The patient died 4 days later. The baby is being monitored by ophthalmology for a diagnosis of retinopathy of prematurity.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;Cholangiocarcinoma is the second most common liver neoplasm, it encompasses neoplasms that depend on the b","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 ","pages":"Article 101842"},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143896053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regression of hepatic fibrosis due to hepatitis C virus (HCV) infection and its associated factors in Mexican population treated with direct-acting antiviral agents. A preliminary study.","authors":"Raúl Ramírez-Marcial,&nbsp;Scherezada M. Mejía-Loza,&nbsp;María del Rosario Herrero-Maceda,&nbsp;Eumir Israel Juárez Valdes","doi":"10.1016/j.aohep.2025.101831","DOIUrl":"10.1016/j.aohep.2025.101831","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>After achieving a sustained viral response with AAD, regression of fibrosis is not always achieved. Studies have been conducted to determine factors that may be involved such as age, BMI, diabetes, dyslipidemia, and steatosis, among others. OBJECTIVE: To determine the factors associated with regression of hepatic fibrosis in patients treated with AAD at the Juarez Hospital in Mexico.</div></div><div><h3>Materials and Patients</h3><div>A retrospective, observational, cross-sectional study was conducted from January 2019 to March 2024 on patients diagnosed with hepatitis C virus infection. The following inclusion criteria were considered: Patients aged 18 or more who underwent treatment with sofosbuvir/velpatasvir 400mg/100mg for 12 weeks or glecaprevir/pibrentasvir 100mg/40mg for 8 weeks and had significant fibrosis (&gt;F2) determined by FIB-4 score and APRI score before the treatment. Exclusion criteria: patients under 18 years of age, co-infection with HBV, and/or incomplete treatment. Patients were divided into 4 groups: GROUP 1: patients without hepatic cirrhosis and without associated comorbidities, GROUP 2: patients without hepatic cirrhosis but with associated comorbidities, GROUP 3: patients with hepatic cirrhosis without associated comorbidities, and GROUP 4: patients with hepatic cirrhosis and associated comorbidities. For each group, FIB-4 score and APRI score were measured at the beginning and after treatment to evaluate differences in fibrosis regression between groups.</div></div><div><h3>Results</h3><div>51 patients were recruited, of whom: 5 patients were part of Group 1. From this group, 40% achieved a decrease in stage APRI and FIB-4 stage after treatment. Group 2: 11 patients, 45% decreased one stage of APRI and FIB-4 score. Group 3: 19 patients, no patient achieved a decrease in APRI and FIB-4 score after treatment. Group 4: 16 patients, only 18.74% achieved a decrease in both APRI and FIB-4 stages after treatment, and the 25% of this group achieved a decrease just in APRI stage..</div></div><div><h3>Conclusions</h3><div>In this preliminary study, a major percentage of patients with and without hepatic cirrhosis plus another associated comorbidity (diabetes, hypertension, dyslipidemia, and/or hepatic steatosis) did not achieve a decrease in APRI and FIB-4 stages after treatment. Therefore, an analysis of variances should be performed to determine which of these factors impact fibrosis regression, and the sample size should be expanded to achieve significant results.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 ","pages":"Article 101831"},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143896144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nopal and Pirfenidone Ameliorate Epididymal Fat Weight and Anthropometric Parameters in a Mouse Obesity Model with Diethylnitrosamine","authors":"Jorge Gutiérrez-Cuevas ,&nbsp;Daniel López-Cifuentes ,&nbsp;Ana S. Sandoval-Rodríguez ,&nbsp;Juan Armendariz-Borunda","doi":"10.1016/j.aohep.2025.101859","DOIUrl":"10.1016/j.aohep.2025.101859","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction and Objectives&lt;/h3&gt;&lt;div&gt;Obesity is associated with liver diseases. Mexico has a high prevalence of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). Nopal and Pirfenidone (PFD) increase insulin signaling and decrease hepatic steatosis in obese mice. We investigated PFD and nopal on anthropometric parameters in obese mice and with diethylnitrosamine (DEN).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and Methods&lt;/h3&gt;&lt;div&gt;Five-six-week-old male C57BL/6J mice were treated with a single dose of DEN (25 mg/kg) and fed with a high fat diet (HFD, 60 kcal% from fat: D12492) for 16 weeks. Animals were provided ad libitum access to food and water. The mice were randomly divided into eight groups (n=5 for each group): normal diet (ND), ND plus DEN (ND+DEN), HFD, HFD plus DEN (HFD+DEN), HFD plus DEN plus supplements (cellulose, maltodextrin, and casein; HFD+DEN+SUPPL), HFD plus DEN plus nopal (HFD+DEN+NOP), HFD plus DEN plus PFD (HFD+DEN+PFD), and HFD plus DEN plus NOP plus PFD (HFD+DEN+NOP+PFD). Freeze-dried nopal in fine powder (7%) were mixed with HFD and PFD (300 mg/kg/day) also were mixed with HFD. PFD dosage was adjusted according to body weight and mixed with the diets three times a week. Food intake was measured three times a week, and measurement of body weight each week. Experiments were done according to ARRIVE guidelines. Statistical significance of anthropometric data was determined for parametric data with one-way ANOVA analysis of variance followed by Tukey's post hoc analysis, statistical analyses were performed using SPSS.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;All HFD mice developed obesity (P≤0.05), and PFD and NOP plus PFD reduced body weight (P≤0.05). Liver weight was increased in HFD, HFD+DEN, and HFD+DEN+SUPPL groups (P≤0.05), and epididymal fat was increased in all HFD mice (P≤0.001), but NOP, PFD, and NOP plus PFD reduced liver weight (P≤0.05) and PFD, and NOP plus PFD decreased epididymal fat (P≤0.05). Heart weight was increased in HFD, HFD+DEN, HFD+DEN+SUPPL, and HFD+DEN+NOP groups (P≤0.05), but NOP (p=0.06), PFD, and NOP plus PFD reduced it (P≤0.001). The heart weight/body weight ratio was reduced in all mice with HFD (P≤0.001), and only NOP plus PFD increased the heart weight/body weight ratio (P≤0.05). Liver weight/body weight ratio tended to increase in HFD and HFD plus DEN, but decreased with NOP, PFD, and NOP plus PFD (P≤0.05). Body weight/tibia length ratio was increased in all HFD mice (P≤0.01) and decreased with PFD and NOP plus PFD (P≤0.05). Heart weight/tibia length ratio was increased in HFD, HFD+DEN, HFD+DEN+SUPPL, and HFD+DEN+NOP (P≤0.01), but decreased with PFD and NOP plus PFD (P≤0.001). Epididymal fat weight/tibia length ratio was increased in all HFD mice (P≤0.001) but decreased with PFD (P=0.07) and NOP plus PFD (P≤0.05) (Figure 1).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;In this study, we showed that intervention with nopal and pirfenidone improved epididymal fat weight and anth","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 ","pages":"Article 101859"},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143896003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Prevalence of the FTO T allele (rs9939609 T>A) and its association with a high risk of Type 2 diabetes or metabolic-associated steatotic liver disease (MASLD) in the Mexican population","authors":"Leonardo Leal-Mercado ,&nbsp;Sonia Román ,&nbsp;Maricruz Sepúlveda-Villegas ,&nbsp;Alexis Jose-Abrego ,&nbsp;Arturo Panduro","doi":"10.1016/j.aohep.2025.101875","DOIUrl":"10.1016/j.aohep.2025.101875","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction and Objectives&lt;/h3&gt;&lt;div&gt;The &lt;em&gt;FTO&lt;/em&gt; rs9939609 (T&gt;A) polymorphism has been associated with obesity and metabolic disorders, including type 2 diabetes and MASLD. This study examined the distribution of the &lt;em&gt;FTO&lt;/em&gt; (T&gt;A) polymorphism in Native and admixed populations and its impact on an admixed Mexican cohort's anthropometric and metabolic profiles.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and Patients&lt;/h3&gt;&lt;div&gt;In this cross-sectional study, we evaluated 684 unrelated adults from various regions of West Mexico, categorizing them into Native, Mestizo (admixed), and Mestizo-Caucasian groups based on ancestry. Genotyping for the &lt;em&gt;FTO&lt;/em&gt; rs9939609 polymorphism was performed using an allele discrimination assay via Real-Time PCR. Given the low prevalence of the A allele among the Mestizo subjects (n=333), the biochemical and anthropometric measurements were adjusted by genotypes AA+AT vs. TT. Anthropometric measurements were assessed using body circumferences and electrical bioimpedance. Metabolic profiles were evaluated by measuring glucose, insulin, triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), aspartate aminotransferase (AST), and alanine aminotransferase (ALT). Metabolic abnormalities were defined as follows: hypercholesterolemia (HCL) with TC ≥200 mg/dL, high LDL-c (H-LDL) with LDL-c ≥130 mg/dL, hypoalphalipoproteinemia (HALP) with HDL-c &lt;40 mg/dL, hypertriglyceridemia (HTG) with TG ≥150 mg/dL, hyperglycemia (HGL) with fasting glucose ≥100 mg/dL, hyperinsulinemia (HINS) with insulin &gt;9 µUI/dL, and insulin resistance (IR) with HOMA-IR ≥2.5. Principal Component Analysis (PCA) was used to visualize genetic divergence focusing on the TT genotype. Univariate and multivariate logistic regression analyses were conducted to assess the risk association between the TT genotype and metabolic abnormalities. Statistical analyses were performed using R Studio and SPSS software.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;The Huicholes Native population exhibited the highest T allele frequency and TT genotype frequency (94% and 89%), followed by Mestizos from Guadalajara (74% and 56%). In contrast, Mestizo-Caucasians from Cuquio had the lowest T allele frequency (28.1%) and the highest A allele frequency (32.4%) within the Mestizo-Caucasian population of Villa Purificación. Genetic distance analysis using PCA based on &lt;em&gt;FTO&lt;/em&gt; TT genotype prevalence revealed that the Mestizo-Caucasian population formed a distinct cluster, while Native populations displayed the highest genetic divergence among groups. When analyzing the Mestizos by genotype (AA+AT vs. TT), no significant differences were found in BMI or body fat percentage. However, metabolic profiles of TT genotype carriers showed higher waist-to-height ratios (0.49±0.08 vs. 0.52±0.07, p&lt;0.001), insulin levels (8.8±5.2 vs. 10.8±7.3 µUI/dL, p&lt;0.041), TG (125.8±65.3 vs. 141.8±66.5 mg/dL, p&lt;0.017), and VLDL-c (25.6±14.2 vs. 29.1±","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 ","pages":"Article 101875"},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143895864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of the CLIF-C AD score to assess readmission in patients with acute decompensation of non-ACLF cirrhosis.","authors":"Cristian A. Oviedo-Garza,&nbsp;Alejandro Peña-Montes,&nbsp;María R. Herrero Maceda,&nbsp;Scherezada M. Loza-Mejia","doi":"10.1016/j.aohep.2025.101876","DOIUrl":"10.1016/j.aohep.2025.101876","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Patients with cirrhosis who require hospitalization due to acute decompensation (ascites, digestive bleeding, hepatic encephalopathy, among others), have a variable adverse prognosis, depending on whether they have acute-on-chronic liver failure (ACLF), the CLIF-C AD test allows to identify the risk of readmission, development of ACLF and mortality.</div></div><div><h3>Materials and Patients</h3><div>A cross-sectional study was carried out between October 2023 and May 2024. The CLIF-C AD test was calculated in patients with decompensated cirrhosis. The results were analyzed using descriptive statistics, frequency analysis, and percentages. Group comparison analysis was performed with Student's T and chi square as appropriate, to determine the sensitivity and specificity of this test, and a ROC curve was performed; Likewise, Kaplan Meyer curves of 2 groups were used according to the CLIF-C AD categorized as 62 or less and greater than 62; having a significant value of p:0.005; The analysis was performed with the statistical program SPSS version 25.</div></div><div><h3>Results</h3><div>There were 40 patients; 32 men and 8 women. Cirrhosis etiology: alcohol 30 patients (75%), MASLD 8 patients (20%), autoimmune hepatitis 2 patients (5%). Cause of decompensation: Upper digestive bleeding in 19 patients (47.5%), urinary infection in 8 patients (20%), tense ascites in 4 patients (10%), spontaneous bacterial peritonitis in 3 patients (7.5%). Findings on admission: ascites 27 patients (67.5%), hepatic encephalopathy 27 patients (67.5%), shock 18 patients (45%). The CLIF-C-AD score with a median of 68 IQR (52-73). Readmission 35 patients (87.5%); The cause of readmission was hepatic encephalopathy in 17 patients (42.5%), upper digestive bleeding in 10 patients (25%), and acute kidney injury in 3 patients (7.5%). Using Student's T, the CLIF-C AD score is determined for those who were readmitted with a mean of 66 and for those who were not readmitted with a mean of 41 (p&lt;0.001). In the ROC curve, the area under the curve was found to be 0.950 with 95% CI (0.890-1.000) p=0.001, sensitivity 77%, specificity 100%, with a Youden point of 62 points; Therefore, it is categorized into 2 groups based on this score for a cumulative incidence of readmission by Kaplan Meier curve, showing a difference between the groups with a Log Rang test of 0.005.</div></div><div><h3>Conclusions</h3><div>The CLIF-C AD score is a practical, adequate, and useful tool to determine the outcome of decompensated cirrhotic patients, which will allow the identification of high-risk patients and the implementation of close follow-up strategies and timely therapeutic adjustment and avoid adverse outcomes. More studies are required and increased sample size.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 ","pages":"Article 101876"},"PeriodicalIF":3.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143895865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}